Cardinal Health: Why This Essential Healthcare Distributor Deserves A Buy Rating

Cardinal Health (CAH) was reiterated with a Buy rating, highlighting defensive fundamentals and strong profitability momentum. Q3FY26 revenue grew 11% and adjusted EPS rose 35%, though GAAP earnings were pressured by higher costs and special items. The stock trades at a premium Forward P/E of 21.64x, with further upside tied to sustained margin gains and improving cash flow.

Analysis

CAH is a quality compounder, but the market has already moved it from "defensive" to "prove-the-margin-trajectory." At ~22x forward earnings, the stock now needs not just top-line growth but sustained mix shift and operating leverage; otherwise the next disappointment is likely multiple compression, not a revenue miss. The immediate setup is therefore more about whether specialty healthcare can lift gross profit dollars faster than reimbursement pressure, freight, and labor than about the headline EPS print.

Second-order beneficiaries are the specialty channel participants and manufacturers that need a reliable distributor; if CAH is taking share, MCK and Cencora likely defend with pricing, service concessions, or working-capital terms, which can leak margin across the group before it shows up in reported growth. The adjusted-vs-GAAP gap is the key tell: if special items remain recurring, the quality of earnings narrative weakens and buybacks/FCF optics stop mattering as much because cash conversion becomes the true constraint.

The contrarian view is that consensus may be underestimating integration and reimbursement complexity in specialty expansion. That business can look accretive for 1-2 quarters, then stall if payer mix shifts, inventory needs rise, or a regulatory/shipping disruption hits. The thesis is falsified if the next 1-2 reports show adjusted EPS growth decelerating while operating margin and free cash flow fail to expand meaningfully; conversely, a clean beat with rising cash conversion would justify a further re-rate over 6-18 months.

Key Decisions for Investors

• Hold a modest long CAH only on dips, not chase: target entry below ~20x forward EPS; upside is another 8-12% if specialty mix and FCF both inflect, but downside is 10-15% if the market decides the premium multiple is not earned.
• Relative-value idea: long CAH / short a basket of lower-quality healthcare defensives (e.g., WBA or XLP proxy) for 1-3 months if the next quarter confirms margin expansion; this isolates idiosyncratic self-help and reduces broad market beta.
• Set an alert on CAH’s next earnings for working-capital intensity and the size/frequency of special items; if either worsens, fade the multiple rather than the earnings growth.
• Watch MCK and COR for defensive pricing response in specialty distribution over the next 1-2 quarters; if they defend share with concessions, CAH’s margin expansion thesis should be cut back quickly.